Investor Relations
Company Profile
LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and other virus infections. The Company operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry.
News Releases
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and U
2024-12-19 15:59:46
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in C
2024-12-12 16:14:21
LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regul
2024-11-07 16:16:46
2024-10-29 16:17:49
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJ
2024-10-25 16:19:14
Events
2024-04-19 16:38:18
2023-09-07 21:11:57
2023-08-15 21:08:07
2023-07-26 21:07:32
2023-05-23 21:06:10